Alerts will be sent to your verified email
Verify Email
AMBALALSA
|
Ambalal Sarabhai Ent
|
Gennex Lab
|
Balaxi Pharma.
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceutical Sector
|
|||
|
R&D as a % of Total Sales
|
0.13 % | n/a | n/a |
|
Financials
|
|||
|
5 yr Average ROE
|
24.68 % | 7.82 % | 29.33 % |
|
5yr average Equity Multiplier
|
2.5 | 1.53 | 1.4 |
|
5yr Average Asset Turnover Ratio
|
0.75 | 0.75 | 1.5 |
|
5yr Avg Net Profit Margin
|
12.49 % | 7.88 % | 11.83 % |
|
Price to Book
|
1.92 | 1.52 | 1.34 |
|
P/E
|
18.97 | 14.74 | 10.54 |
|
5yr Avg Cash Conversion Cycle
|
-44.39 Days | 43.23 Days | 133.11 Days |
|
Inventory Days
|
34.61 Days | 49.12 Days | 68.7 Days |
|
Days Receivable
|
54.38 Days | 50.53 Days | 81.67 Days |
|
Days Payable
|
160.49 Days | 75.36 Days | 60.92 Days |
|
5yr Average Interest Coverage Ratio
|
10.58 | 6.21 | 92.41 |
|
5yr Avg ROCE
|
29.87 % | 11.17 % | 40.34 % |
|
5yr Avg Operating Profit Margin
|
4.12 % | 10.47 % | 18.05 % |
|
5 yr average Debt to Equity
|
0.39 | 0.18 | 0.05 |
|
5yr CAGR Net Profit
|
-16.58 % | 43.63 % | n/a |
|
5yr Average Return on Assets
|
9.85 % | 5.16 % | 20.09 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
31.35 % | 18.42 % | 65.99 % |
|
Share Pledged by Promoters
|
0.0 | 23.87 % | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.59 % | -3.63 % | -6.87 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Ambalal Sarabhai Ent
|
Gennex Lab
|
Balaxi Pharma.
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Operating Profit Break-Up
|
Operating Profit Break-Up
|
-
|
-
|
|
Capex
|
Capex
|
-
|
-
|
|
Asset Break-Up
|
Asset Break-Up
|
-
|
-
|